SoftWriters’ FrameworkLTC® Platform Integrates FDB’s Meducation® Solution to Enable Multilingual Prescription Labeling

Leading Purpose-Built Pharmacy Management System for Long-Term Care Facilities to Translate Prescription Instructions into Nearly 30 Languages, Improving Patient Understanding and Medication Adherence

FDB (First Databank, Inc.), the leading provider of drug and medical device knowledge that helps healthcare professionals make precise decisions, today announced an agreement with SoftWriters to integrate FDB’s Meducation® solution into its FrameworkLTC® pharmacy management platform to seamlessly translate prescription labels into any of nearly 30 preferred languages requested by patients.

The integration aligns with new state regulations, most recently announced in Nevada and Oregon, that require pharmacies to offer prescription labels in a language other than English at the request of the patient or caregiver. Oregon’s law went into effect this year and Nevada’s law was approved by its governor this year and will go into effect in July 2022. California’s and New York’s multilingual prescription label laws each have been on the books for several years.

Research has shown that patients receiving simplified, personalized medication instructions in their primary language demonstrate significantly greater understanding of their prescriptions than those receiving generic instructions.

“More and more state leaders are recognizing that offering prescription labels and educational materials in a patient’s preferred language can improve their health literacy and adherence to medication regimens,” said Charles Lee, MD, Senior Director of Clinical Knowledge for FDB. “SoftWriters is taking the lead in this regard by integrating FDB’s Meducation solution into its market-leading platform, which will save pharmacists time in fulfilling orders and improve patients’ understanding of their therapies, leading to better outcomes.”

Accessing Meducation’s translated prescriptions capability is simple for pharmacists using FrameworkLTC and eliminates the need to deviate from their existing fulfillment workflow. When the physician submits the prescription order, including the dosing and refill instructions, or “sig,” Meducation’s Natural Language Processing (NLP) capabilities transform the sig—which can come in one of millions of variations—into a standardized, translated format.

When using this new solution, a pharmacist simply selects the patient’s preferred language within FrameworkLTC that is powered by FDB’s Meducation API. The translation capability updates the label to the preferred language in less than a second. In addition, the image-based format provides a method to support older labeling printers that may not have built-in support for some fonts or right-to-left languages.

“Multilingual support is another example of how SoftWriters is dedicated to meeting a market need while improving our user experience through the continual optimization of our FrameworkLTC purpose-built pharmacy management platform,” said Deepika Devarajan, Vice President, Product at SoftWriters. “FDB’s robust and seamless solution is the perfect addition to our highly automated platform that we anticipate will continue to streamline pharmacist workflows and drive patient outcomes.”

Complete Patient Medication Education Solution

Meducation includes more than prescription label translation support. It is a complete patient medication education and engagement solution that can enable organizations to provide simplified, personalized medication instructions to all patients. All material is written at a 5th to 8th grade level with supporting pictograms and calendars, and is available in a range of font sizes. Beyond printed materials, a patient’s Meducation content can be accessed through a web browser, patient portal or mobile app.

“Multilingual support is an important element of our broader patient medication education solution and one we are pleased to share with more pharmacy teams across all healthcare settings, offering additional languages as they become available,” said Dr. Lee. “Not only does the near-real-time language translation save pharmacists time and help them practice more efficiently, but it also helps them better care for and communicate with and support the patient and their caregivers.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”